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indirect method of estimating intra-fraction motion, because it is based on the comparison of prostate position on two EPID of
Mv: Before and immediately after the session ends. The position of the gold markers on each daily pair of EPIs was compared
to their intended position, as seen on the reference DRR, to determine isocenter placement error, by using the marker matching
functions. Patients were treated in the supine position using IMRT. The prescription dose was 76Gy in 38 fractions. The PTV was
required to be covered by 95% of the prescription dose. The mean intrafraction motion (±SD) was 0.02±0.19 cm, 0.11±0.18 cm
and 0.11±0.16 cm along the L–R, S–I and A–P axes respectively. If all pre-treatment isocenter placement errors have fully were
completely corrected, leaving intra-fraction motion as the only variable affecting during-treatment isocenter placement, PTV
margins of 0.36 cm, 0.36 cm and 0.26 cm would be required along the L–R, S–I and A–P axes respectively, to give a 95% probability
of complete CTV coverage on any given treatment day. Concluding, while our estimates of CTV to PTV margin requirements
along the L–I and S–I axes are comparable to other reports, our estimate of margin requirement along the A–P axis appears to be
slightly less than in the other reports using image guidance.
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The combination of transurethral resection of the bladder, chemotherapy and radiation therapy is a validated approach to bladder
preservation in cancer muscle-invasive. However there is very little information on the patterns of treatment with radiotherapy.
The aim of this study was to assess therapeutic approaches to muscle-invasive bladder cancer at Radiation Oncology Services
in Spain. A speciﬁcally designed questionnaire was submitted to 86 Radiation Oncology Services in Spain through the SEOR
and URONCOR via e-mail in 2010, to assess their therapeutic approach to bladder cancer over the 2005–2009 period. A total of 26
centers (30.5% of the total, ofwhich 96%were public and 81%were university hospitals) answered the questionnaire. 92% reported
to have a Urology Tumor Board that makes consensual decisions on muscle-invasive bladder carcinomas. Treatment approaches
was reported to be systematically determined by the Board at 92%. A total of 100% of hospitals provide radical 3D conformal
radiation therapy and three hospitals also performed IMRT. The radiation therapy scheme designed for “bladder preservation”
was reported to include both options: single-dose series (continuous irradiation without response evaluation after 40–45Gy) or
fractionated series (irradiation with response evaluation by cystoscopy and by radical transurethral resection after 40–45Gy). A
total of 64% of hospitals “always” perform single-dose series, of which 19% “sometimes” perform fractionated series. Twenty
percent (ﬁve hospitals) “exclusively” perform fractionated series, with an average response evaluation interval of seven days.
The average of patients on radical radiation therapy in 2005 was 51%; 47% in 2008, and 43% in 2009, with a statistically signiﬁcant
decreasing tendency (p=0.02). At public hospitals in Spain, there are multidisciplinary urology tumor boards where urologists,
radiation oncologists and medical oncologists collaborate to systematically make consensual decisions. In this period there is a
signiﬁcant downward trend in the use of radiotherapy for bladder sparing.
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Purpose. Postoperative radiotherapy in prostate cancer patients treated with prostatectomy improves biochemical progression-
free survival (BPFS) and in selected patients prolongs the overall survival. Pelvic IMRT in this group of patients has been poorly
explored regarding acute and late toxicity compared with 3DCRT. We retrospectively analyze patients treated in our institution
with IMRT after prostatectomy.
Material and methods. Patients with pT3-T4 and/or N+ and/or positive surgical margin received adjuvant IMRT (aIMRT). Patients
with biochemical failure (PSA>0.1ng/ml) after prostatectomy were treated with salvage IMRT (sIMRT). Dose-range administered
was 64–72Gy in 30–33 fractions. High-risk or very high-risk patients received long-term androgen deprivation therapy.
Results. Ninety-six patients were analyzed, 34 were treated with aIMRT and 62 patients sIMRT. All patients completed the treat-
ment protocol. The median time intervals from surgery to aIMRT and sIMRT were 3-months and 19.5-months, respectively.
Adverse events were recorded following the CTCAE v4.0 score. Grade 1–2 and grade 3–4 acute GU toxicity were observed in 52
patients (54.2%) and 1 patient (1.0%), respectively. Thirty-seven patients (38.5%) had grade 1–2 acute GI toxicity and no patient
with grade 3–4 GI complications was recorded. Eighty-ﬁve patients were evaluated for late complications and grade 1–2 chronic
